AstraZeneca’s

AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. The Institute for Clinical and… Read More »

AstraZeneca’s $39B Alexion buyout scores EU blessing but still awaits key nod from the UK

AstraZeneca’s $ 39 billion takeover of rare disease specialist Alexion has another regulatory blessing in the bag, but the pair are still holding out for a key nod from the U.K. to settle the deal. AstraZeneca on Tuesday said that the European Union has approved its acquisition of Boston-based Alexion, inching closer toward its goal… Read More »